KYMR
Kymera Therapeutics, Inc. NASDAQ Listed Aug 21, 2020$89.91
+0.01%
vs $89.90
Mkt Cap $7.4B
52w Low $36.65
80.3% of range
52w High $103.00
50d MA $83.00
200d MA $73.30
P/E (TTM)
-24.4x
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.1x
ROE
-19.7%
P/FCF
-32.4x
RSI (14)
63.50
ATR (14)
$4.05
Beta
2.29
50d MA
$83.00
200d MA
$73.30
Avg Volume
562.2K
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
200 Arsenal Yards Boulevard · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.89 | -0.71 | +20.2% | 81.51 | +4.8% | -0.5% | -0.4% | +3.6% | -1.1% | +4.3% | — |
| Feb 26, 2026 | BMO | -0.78 | -0.97 | -23.8% | 90.68 | -5.2% | +4.8% | -3.9% | -1.4% | -4.2% | -0.3% | — |
| Nov 4, 2025 | BMO | -0.71 | -0.90 | -26.8% | 59.72 | -6.6% | +0.3% | -0.0% | +1.9% | -3.8% | +4.4% | — |
| Aug 11, 2025 | BMO | -0.83 | -0.95 | -14.5% | 40.62 | -6.1% | -7.2% | +5.8% | +2.2% | +2.0% | +2.6% | — |
| May 9, 2025 | BMO | -0.92 | -0.82 | +10.9% | 30.77 | +9.3% | -2.3% | +7.0% | -3.2% | -4.5% | +0.9% | — |
| Feb 27, 2025 | BMO | -0.76 | -0.88 | -15.8% | 35.36 | -3.8% | -14.5% | +3.6% | -3.8% | +1.7% | +3.3% | — |
| Oct 31, 2024 | BMO | -0.83 | -0.82 | +1.2% | 47.67 | -6.1% | -3.1% | +0.6% | +1.3% | +1.3% | +3.8% | — |
| Aug 7, 2024 | BMO | -0.69 | -0.58 | +15.9% | 41.42 | +9.8% | -2.7% | +4.2% | -1.4% | +2.6% | +1.2% | — |
| May 2, 2024 | BMO | -0.73 | -0.69 | +5.5% | 36.24 | -0.2% | +0.2% | +3.0% | +2.4% | +0.4% | +0.2% | — |
| Feb 22, 2024 | BMO | -0.44 | -0.25 | +43.2% | 38.67 | +2.9% | +4.7% | +3.3% | +3.8% | +0.3% | -0.7% | — |
| Nov 2, 2023 | BMO | -0.73 | -0.90 | -23.3% | 11.55 | -12.6% | +4.6% | +18.1% | +0.9% | +13.6% | -2.5% | — |
| Aug 3, 2023 | BMO | -0.70 | -0.67 | +4.3% | 21.50 | +9.3% | +11.1% | -5.5% | -11.0% | -0.8% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | Canaccord Genuity | Initiates | Buy | $106 | $82.71 | $84.08 | +1.7% | +4.3% | -1.9% | +1.7% | -2.3% | -0.7% |
| Mar 3 | UBS | Maintains | Buy → Buy | — | $90.10 | $87.41 | -3.0% | -4.2% | -0.3% | -3.0% | -0.0% | +1.9% |
| Mar 2 | Citigroup | Maintains | Buy → Buy | — | $91.35 | $89.24 | -2.3% | -1.4% | -4.2% | -0.3% | -3.0% | -0.0% |
| Mar 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $91.35 | $89.24 | -2.3% | -1.4% | -4.2% | -0.3% | -3.0% | -0.0% |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $90.68 | $86.00 | -5.2% | +4.8% | -3.9% | -1.4% | -4.2% | -0.3% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $90.68 | $86.00 | -5.2% | +4.8% | -3.9% | -1.4% | -4.2% | -0.3% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $75.62 | $75.16 | -0.6% | +2.1% | +0.6% | -2.3% | +4.8% | -0.7% |
| Jan 28 | Barclays | Maintains | Overweight → Overweight | — | $72.15 | $72.54 | +0.5% | -1.4% | +3.9% | -1.7% | +4.0% | +2.1% |
| Jan 15 | BTIG | Maintains | Buy → Buy | — | $75.21 | $75.37 | +0.2% | -5.4% | -2.2% | -2.0% | +3.8% | +2.9% |
| Jan 6 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $72.41 | $70.66 | -2.4% | +1.5% | +4.4% | -2.2% | -0.3% | -2.2% |
| Dec 22 | B. Riley Securities | Maintains | Buy → Buy | — | $83.99 | $84.73 | +0.9% | +0.4% | -1.0% | -0.5% | -2.2% | -1.2% |
| Dec 16 | RBC Capital | Maintains | Outperform → Outperform | — | $85.68 | $86.32 | +0.7% | -1.7% | -2.5% | -3.0% | +5.5% | +0.4% |
| Dec 11 | Mizuho | Maintains | Outperform → Outperform | — | $89.89 | $90.74 | +0.9% | -2.3% | +2.1% | -4.5% | -1.7% | -2.5% |
| Dec 11 | Stephens & Co. | Maintains | Overweight → Overweight | — | $89.89 | $90.74 | +0.9% | -2.3% | +2.1% | -4.5% | -1.7% | -2.5% |
| Dec 10 | JP Morgan | Maintains | Overweight → Overweight | — | $86.88 | $93.07 | +7.1% | +3.5% | -2.3% | +2.1% | -4.5% | -1.7% |
| Dec 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Barclays | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Leerink Partners | Maintains | Outperform → Outperform | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | BTIG | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Citigroup | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Jefferies | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Truist | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Dec 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | +3.5% | -2.3% | +2.1% | -4.5% |
| Nov 26 | Truist | Maintains | Buy → Buy | — | $66.04 | $66.89 | +1.3% | +2.8% | +0.0% | -1.5% | -3.9% | +2.7% |
| Nov 5 | Barclays | Maintains | Overweight → Overweight | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.9% | -3.8% | +4.4% | +3.4% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.9% | -3.8% | +4.4% | +3.4% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.9% | -3.8% | +4.4% | +3.4% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $58.32 | $59.19 | +1.5% | -4.3% | +3.5% | +1.4% | +3.9% | +1.8% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $60.46 | $60.20 | -0.4% | -1.0% | +1.1% | -3.6% | -4.3% | +3.5% |
| Oct 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $56.60 | $56.30 | -0.5% | -3.4% | +2.5% | +3.4% | -0.6% | -1.1% |
| Sep 30 | Truist | Maintains | Buy → Buy | — | $58.50 | $58.93 | +0.7% | -3.2% | -3.4% | +2.5% | +3.4% | -0.6% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.12 | $49.39 | +2.6% | +6.3% | -4.0% | +3.8% | -0.3% | +3.2% |
| Jun 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $45.71 | $46.43 | +1.6% | -3.5% | -1.1% | +1.8% | +0.2% | +0.6% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.47 | $45.51 | -2.1% | -1.6% | -3.5% | -1.1% | +1.8% | +0.2% |
| Jun 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $46.47 | $45.51 | -2.1% | -1.6% | -3.5% | -1.1% | +1.8% | +0.2% |
| Jun 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $43.13 | $44.95 | +4.2% | +1.0% | +1.6% | +7.7% | -0.1% | -1.0% |
| Jun 3 | B. Riley Securities | Upgrade | Neutral → Buy | — | $43.13 | $44.95 | +4.2% | +1.0% | +1.6% | +7.7% | -0.1% | -1.0% |
| Jun 3 | JP Morgan | Maintains | Overweight → Overweight | — | $43.13 | $44.95 | +4.2% | +1.0% | +1.6% | +7.7% | -0.1% | -1.0% |
| May 13 | UBS | Maintains | Buy → Buy | — | $32.17 | $32.30 | +0.4% | -3.2% | -4.5% | +0.9% | +0.8% | -0.2% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $30.07 | $31.37 | +4.3% | +7.0% | -3.2% | -4.5% | +0.9% | +0.8% |
| May 12 | B. Riley Securities | Maintains | Neutral → Neutral | — | $30.07 | $31.37 | +4.3% | +7.0% | -3.2% | -4.5% | +0.9% | +0.8% |
| May 12 | BofA Securities | Maintains | Neutral → Neutral | — | $30.07 | $31.37 | +4.3% | +7.0% | -3.2% | -4.5% | +0.9% | +0.8% |
| May 12 | JP Morgan | Maintains | Overweight → Overweight | — | $30.07 | $31.37 | +4.3% | +7.0% | -3.2% | -4.5% | +0.9% | +0.8% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.25 | $30.20 | -0.2% | +3.6% | -3.8% | +1.7% | +3.3% | +2.6% |
| Jan 21 | Stephens & Co. | Maintains | Overweight → Overweight | — | $40.61 | $41.65 | +2.6% | +7.6% | +1.0% | +0.2% | +0.3% | -7.1% |
| Dec 27 | Leerink Partners | Maintains | Outperform → Outperform | — | $42.02 | $41.98 | -0.1% | -4.5% | -2.0% | +2.3% | +1.6% | +1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 600 | $82.08 | $49K | 44,018 | -0.29% | +2.69% |
| May 27, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 3,679 | $81.50 | $300K | 44,618 | -0.29% | +2.69% |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 551 | $80.71 | $44K | 48,297 | -0.29% | +2.69% |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 4,500 | $80.02 | $360K | 48,848 | -0.29% | +2.69% |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 3,800 | $79.39 | $302K | 53,348 | -0.29% | +2.69% |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 324 | $79.17 | $26K | 57,148 | -0.29% | +2.69% |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | Sell | 3,730 | $78.36 | $292K | 57,472 | -0.29% | +2.69% |
| May 11, 2026 | Ridloff Elena | — | Sell | 3,000 | $87.00 | $261K | — | -0.65% | -3.09% |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 936 | $82.45 | $77K | 666,195 | -0.54% | +4.29% |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 12,059 | $81.70 | $985K | 667,131 | -0.54% | +4.29% |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 17,005 | $80.74 | $1.4M | 679,190 | -0.54% | +4.29% |
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.
Apr 30
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis from this filing excerpt, as it contains only standard signature blocks without substantive disclosure of what material event triggered the 8-K filing.
Mar 27
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics appointed veteran biopharma executive Neil Graham as Chief Development Officer while advancing multiple clinical programs, including KT-621 in atopic dermatitis and asthma with data readouts expected through 2027.
Feb 26
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics established an at-the-market equity offering agreement with TD Cowen, allowing the company to sell shares up to a specified amount with TD Cowen receiving up to 3.0% commission on proceeds.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 11,699,950 | $974M | Added | Mar 2026 |
| 2 | Avoro Capital Advisors Llc | 7,474,747 | $623M | — | Mar 2026 |
| 3 | Atlas Venture Life Science Advisors, Llc | 4,578,008 | $381M | Reduced | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 2,880,324 | $240M | New | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 2,874,056 | $239M | New | Mar 2026 |
| 6 | Capital Research Global Investors | 1,673,275 | $139M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 1,023,852 | $85M | Added | Mar 2026 |
| 8 | Frontier Capital Management Co Llc | 635,957 | $49M | Added | Dec 2025 |
| 9 | Deerfield Management Company, L.p. | 561,170 | $47M | — | Mar 2026 |
| 10 | Morgan Stanley | 548,036 | $43M | Reduced | Dec 2025 |
| 11 | Northern Trust Corp | 494,439 | $41M | Added | Mar 2026 |
| 12 | Jennison Associates Llc | 496,665 | $39M | Reduced | Dec 2025 |
| 13 | Pictet Asset Management Holding Sa | 483,199 | $38M | Added | Dec 2025 |
| 14 | Braidwell Lp | 454,259 | $35M | Added | Dec 2025 |
| 15 | Franklin Resources Inc | 361,772 | $30M | Added | Mar 2026 |
| 16 | Alyeska Investment Group, L.p. | 342,698 | $29M | Reduced | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 289,416 | $24M | Added | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 285,871 | $24M | Added | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 256,501 | $21M | Reduced | Mar 2026 |
| 20 | Rtw Investments, Lp | 240,000 | $20M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$7.40B
Enterprise Value
$6.74B
P/E (TTM)
-24.36x
Forward P/E
—
PEG Ratio
-0.89x
P/B
4.80x
P/S
193.55x
P/FCF
-32.37x
EV/EBITDA
—
Shares Out
84.4M
Financials (TTM)
Revenue
$39.2M
Net Income
-$311.4M
EBITDA
-$303.1M
Free Cash Flow
-$234.3M
Op Cash Flow
-$232.9M
EPS Basic
$-3.69
EPS Diluted
$-3.69
EPS Forward
$-3.71
Gross Margin
100.0%
Op Margin
-891.3%
Net Margin
-794.4%
Balance Sheet
Total Assets
$1.74B
Total Liab.
$163.1M
Total Equity
$1.58B
Cash
$848.3M
LT Debt
$0
Book Value/Sh
$18.72
Debt/Equity
0.05x
Current Ratio
10.47
Quick Ratio
10.47
Returns & Growth
ROE
-19.7%
ROA
-17.9%
ROIC
-20.9%
Rev Growth YoY
-16.7%
EPS Growth YoY
-23.8%
Price Returns
2W
-3.6%
1M
+0.4%
3M
-10.9%
6M
+19.9%
12M
+174.7%
Technicals
52W High
$103.00
52W Low
$36.65
50d MA
$83.00
200d MA
$73.30
RSI (14)
63.50
ATR (14)
$4.05
Beta
2.29
Avg Volume
562K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$117.06
High
$138.00
Low
$90.00
Median
$118.50
Data updated apr 25, 2026 6:18pm
· Source: financialmodelingprep.com